Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (DE:137)
FRANKFURT:137
137 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€2.52 - €6.42
Previous CloseN/A
Volume0.00
Average Volume (3M)11.00
Market Cap
$364.03M
Enterprise Value€126.91M
Total Cash (Recent Filing)$54.53M
Total Debt (Recent Filing)$15.30M
Price to Earnings (P/E)―
Beta1.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding59,708,652
10 Day Avg. Volume0
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.36
Forecast
1Y Price Target
€9.67Price Target Upside68.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalReproxalap has met FDA draft guidance requirements of 2 well-controlled studies for signs and symptoms of dry eye disease.
Partnership OpportunitiesApproval would likely lead AbbVie to exercise the option to co-commercialize reproxalap, triggering a $100M milestone payment to Aldeyra.
Bears Say
Manufacturing RisksA manufacturing CRL would jeopardize the option for reproxalap, despite double CRLs being rare for novel drugs.
---
Options Prices
Currently, No data available
---
Ownership Overview
19.01% Insiders
11.23% Mutual Funds
26.63% Other Institutional Investors
34.32% Public Companies and Individual Investors
137 FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was €2.52 and its highest was €6.42 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $364.03M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Mar 07, 2024. The company reported -€0.076 earnings per share for the quarter, beating the consensus estimate of -€0.106 by €0.03.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 59,708,652 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -€0.076 in its last earnings report, beating expectations of -€0.106. Following the earnings report the stock price went up 3.524%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in DE:137
---
Aldeyra Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.67 (68.77% Upside)
€9.67 (68.77% Upside)
Blogger Sentiment
Bullish
DE:137 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $10.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
82.87%
12-Months-Change
Fundamentals
Return on Equity
-58.54%
Trailing 12-Months
Asset Growth
-29.48%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
---
137 Stock 12 Month Forecast
Average Price Target
€9.67
▲(68.77% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Xoma
―
Ocular Therapeutix
―
Adverum Biotechnologies
―
Kodiak Sciences
―
Best Analysts Covering 137
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+46.68%
reiterated a buy rating 10 days ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +46.68% per trade.
---